# Gila Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/gila-therapeutics

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.gilatherapeutics.com
- Total disclosed funding: $2.6M
- Latest round: Series A (Mar 4, 2023)
- Investors on record: 2

## About

Based in Minnesota, US, and founded in 2014, Gila Therapeutics, Inc. operates as a biotechnology company that develops and provides pharmaceutical therapies for metabolic diseases. In April 2017, the firm raised USD 0.76 million in venture funding. The firm as of August 2023, is led by its President and CEO, Scott Schorer.

The biotech company has developed a lingual signaling PYY or Neural Signaling platform for the treatment of obesity, cardiometabolic disorders, type 2 diabetes, and associated metabolic disorders. The company’s therapeutic platform leverages a biological pathway to activate specific areas of the brain responsible for regulating food intake and metabolism via oral receptors, avoiding side effects such as nausea. As of August 2023, Gila has completed its Lingual PYY’s phase 1 trial and has multiple topical lingual hormone targets including GLP-1, amylin, leptin, etc. under development.

## Funding rounds

- Series A, Mar 4, 2023 — Argonautic Ventures
- Series A, Jan 11, 2017 — Argonautic Ventures
- Series A, Apr 15, 2016, $2.6M — Broadview Ventures

## Investors

- Broadview Ventures (https://capitalatlas.ai/funds/broadview-ventures) — Series A
- Argonautic Ventures (https://capitalatlas.ai/funds/argonautic-ventures) — Series A